Results 11 to 20 of about 1,869 (168)

Lebrikizumab in the Personalized Management of Asthma [PDF]

Biologics: Targets and Therapy, 2012
Neil C Thomson,1 Manish Patel,2 Andrew D Smith21Institute of Infection, Immunity, and Inflammation, University of Glasgow and Respiratory Medicine, Gartnavel General Hospital, Glasgow, UK; 2Department of Respiratory Medicine, Wishaw Hospital, Wishaw ...
Neil C. Thomson, Andrew D Smith
exaly   +12 more sources

Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis

Journal of Asthma and Allergy, 2020
Tiffany Y Loh,1 Jennifer L Hsiao,2 Vivian Y Shi1 1University of Arizona, Division of Dermatology, Tucson, AZ, USA; 2University of California Los Angeles, Division of Dermatology, Los Angeles, CA, USACorrespondence: Vivian Y ShiDivision of Dermatology ...
Vivian Y Shi, Jennifer L Hsiao, Tiffany Y Loh   +2 more
exaly   +7 more sources

Profile of lebrikizumab and its potential in the treatment of asthma

Journal of Asthma and Allergy, 2015
Diego Jose Maselli,1 Holly Keyt,1 Linda Rogers,2 1Department of Medicine, Division of Pulmonary Diseases and Critical Care, University of Texas Health Science Center at San Antonio, San Antonio, TX, 2Pulmonary, Critical Care, and Sleep Medicine ...
Maselli DJ, Keyt H, Rogers L
doaj   +6 more sources

Managing Atopic Dermatitis with Lebrikizumab – The Evidence to Date

Clinical, Cosmetic and Investigational Dermatology, 2022
Angelina Labib, Teresa Ju, Gil Yosipovitch Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami Itch Center, University of Miami Miller School of Medicine, Miami, FL, USACorrespondence: Gil Yosipovitch, Email gyosipovitch@med.miami.
Labib A, Ju T, Yosipovitch G
doaj   +3 more sources

Efficacy of Lebrikizumab on Pruritus: A Narrative Review. [PDF]

Adv Ther
Atopic dermatitis (AD) is a chronic, relapsing, and heterogeneous skin disease characterized by eczematous morphology and intense pruritus, significantly impacting the quality of life of affected individuals. A primary cytokine implicated in AD is interleukin-13 (IL-13), which directly drives pruritus skin sensitization, contributing to pruritus ...
Yosipovitch G, Kim BS, Ständer S, Elmariah SB, Prajapati VH, Kabashima K, Gallo G, Rueda MJ, Pierce E, Ding Y, Kwatra SG.   +10 more
europepmc   +5 more sources

Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment [PDF]

Dermatology and Therapy
Introduction Lebrikizumab is a novel monoclonal antibody with established efficacy in patients with moderate-to-severe atopic dermatitis (AD) in multiple Phase 3 trials.
Jonathan I. Silverberg, Andreas Wollenberg, Linda Stein Gold, James Del Rosso, Gil Yosipovitch, Peter Lio, Jose-Manuel Carrascosa, Gaia Gallo, Yuxin Ding, Zhenhui Xu, Marta Casillas, Evangeline Pierce, Helena Agell, Sonja Ständer   +13 more
doaj   +4 more sources

Lebrikizumab: First Approval

Drugs
Lebrikizumab (Ebglyss®) is a subcutaneous recombinant humanized IgG4 anti-IL-13 monoclonal antibody developed by Almirall S.A. and Eli Lilly and Company for the treatment of atopic dermatitis (AD). In November 2023, lebrikizumab was approved in the EU for the treatment of moderate-to-severe AD in adults and adolescents 12 years and older with a body ...
Susan Keam (4873372)
openaire   +3 more sources

Budget Impact Analysis of Lebrikizumab for Treating Severe Atopic Dermatitis [PDF]

Dermatology and Therapy
Introduction Lebrikizumab is a novel monoclonal antibody that targets interleukin-13, a pivotal factor in atopic dermatitis (AD). Previous studies revealed a positive benefit–risk profile of lebrikizumab as treatment for patients with moderate-to-severe ...
Ippazio Cosimo Antonazzo, Giampiero Girolomoni, Cataldo Patruno, Roberto Langella, Veronica Ottobrino, Lorenzo Giovanni Mantovani, Paolo Angelo Cortesi   +6 more
doaj   +2 more sources

Lebrikizumab (Ebglyss)

Canadian Journal of Health Technologies
Canada’s Drug Agency (CDA-AMC) recommends that Ebglyss should not be reimbursed by public drug plans for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents aged 12 years and older with a body weight of at least 40 kg, whose disease is not adequately controlled with topical prescription therapies or when those ...
CDA-AMC
openaire   +2 more sources

The Role of Lebrikizumab in the Treatment of Atopic Dermatitis in the Adult Population

Immunotherapy, 2023
Although there are many atopic dermatitis (AD) treatments, finding a long-term medication with minimal side effects can be difficult. This review characterizes lebrikizumab as AD treatment in adults. A literature search was conducted to examine lebrikizumab's role in treating moderate to severe AD.
Stuti Prajapati, Mohammad Fardos, Amar D Desai, Steven R Feldman   +3 more
openaire   +3 more sources